INTRODUCTION
Although the prognosis of patients with differentiated thyroid carcinoma (DTC) is favorable, recurrence is noted in up to 30% of such patients (1) (2) (3) (4) (5) . Until recent years, serum thyroglobulin (Tg) measurement and the [ (6) (7) (8) (9) . Because the most common site of recurrence is the cervical lymph nodes, neck ultrasonography (US) may also be helpful in early detection of small cervical metastases (10) (11) (12) . However, a diagnostic dilemma is posed by patients who exhibit increased levels of Tg, in the absence of detection of recurrent cancer using conventional imaging tools such as the iodine-131 whole-body scanning (the [ 131 I] scan) or neck US. Therefore, advanced diagnostic imaging permitting anatomical tumor localization has been used to accurately detect both iodine-and non-iodineavid recurrence; the relevant modalities include positron emission tomography (PET) using either iodine-124 124 I]-PET are both performed before considering whether repeated high-dose radioiodine (RI) treatment is appropriate, unnecessary RI may be excluded, and further optimal management such as surgery or irradiation can be usefully indicated.
The benefits of [ centrate iodine when Tg levels are elevated demand the use of imaging tools other than the [ 131 I] scan. Cervical US is another valuable tool for treatment of recurrent DTC. However, it is also necessary to perform whole-body assessment of disease extent, using a different diagnostic technique. Although recurrent or metastatic DTC tumors grow rather slowly, such tumors consume more glucose than does normal tissue. Consequently, use of [ 18 F]-FDG-PET has been suggested to be valuable in patients who are negative (in terms of tumor recurrence) on conventional imaging but who show elevated Tg levels. The technique has been used to detect both local DTC recurrence and distant metastasis (9, (14) (15) (16) (17) (18) .
Recently, [ 124 I]-PET has emerged as a valuable diagnostic tool for the detection of recurrent or residual DTC disease, and the data afforded are helpful in the planning of therapy during follow-up of DTC patients (13, (19) (20) (21) (22) (23) .
[
124 I]-PET imaging may offer a higher sensitivity than the conventional [ 131 I] scan because the spatial resolution of the former modality is greater. Moreover, the recent introduction of combined PET/CT (computed tomography) scanners allows thyroid cancers to be imaged using a high-resolution PET technique. This may increase the clinical application of such imaging in thyroid cancer patients because detailed anatomical information is obtained and iodine-positive tissue can be located (22) .
The aim of the present study was to prospectively evaluate the utility of [ 
MATERIALS AND METHODS

Inclusion criteria
Between July 2009 and June 2010, 19 patients with histologically proven DTC were studied. All patients had previously undergone total thyroidectomy and more than one session of postoperative RI therapy; the cumulative administered mean dose was 10,905 MBq (range, 5,500-18,500 MBq). At a mean of 16 months (range, 9-41 months) of follow-up after the last RI therapy session, all patients showed increasing pathological Tg levels (Tg > 9-10 ng/mL) after TSH stimulation (TSH > 30 mU/L). However, neither tumor recurrence nor metastasis could be detected in any patient by post-therapeutic [ 131 I] scanning, neck US, or chest radiography. Patients with obvious cervical pathology in US or positive fine-needle aspiration cytology (FNAC) were excluded from the study.
Study protocol
On the first day (D1) of the study, blood and urine were collected for routine examination; to measure blood TSH, Tg, and antiTg antibody levels; and to assess urine iodine excretion after 4 weeks of levothyroxine withdrawal (Fig. 1) . All patients had consumed a low-iodine diet for the prior 2 weeks, following written instructions and assisted by a dietician. F]-FDG. All patients were instructed to rest comfortably for 60 min and to empty the bladder before scanning. Whole-body PET/CT images were obtained using a Discovery ST scanner (GE Healthcare, Milwaukee, WI). Seven or eight frames (3 min/frame) of emission PET data were acquired in the two-dimensional mode after noncontrast CT scans had been performed from the base of the skull to the upper thigh (tube rotation time of 1 sec per revolution; 120 kV; 60 mA; 7.5 mm per rotation; and an acquisition time of 60.9 sec for a scan length of 867 mm). Emission PET images were reconstructed via non-contrast CT using an iterative method (ordered-subsets expectation maximization with two iterations and 30 subsets; field of view 600 mm; slice thickness 3.27 mm). Attenuationcorrected PET/CT images were reviewed on an Xeleris workstation (GE Healthcare). All images were independently interpreted by two experienced nuclear medicine physicians and screened for "hot spots" indicative of hypermetabolic abnormalities.
On day 11 (D11) of the study, 24 hr after administration of an 23.9 sec for a scan length of 804 mm). Subsequently, seven or eight frames (5 min per frame) of emission PET data were acquired in the two-dimensional mode and reconstructed via CT using an iterative method (software from General Electric Medical Systems; ordered-subsets expectation maximization with two iterations and 21 subsets; field of view 600 mm; slice thickness 3.27 mm). 
Data analysis
Ethics statement
The work was reviewed and approved by the institutional review board of Ajou University Hospital (#AJIRB-CRO-09-068). Written informed consent was obtained from each patient.
RESULTS
All participants underwent [ 0%) . In contrast, the remaining three patients (37.5%) were false-positives upon FDG-PET imaging. This was confirmed by histological findings or via use of other radiological information, and subsequent measurement of Tg levels during follow-up. The details of the additional radiological imaging tests conducted (neck CT/MRI, chest CT, or FNAC) are listed in Table 2 . Fig. 2 (Table 3) . The treatment outcomes were: stable disease in six patients, re- 124 I]-PET/CT were performed before repeated high-dose RI treatment was considered, such an evaluation would facilitate diagnostic accuracy and might avoid unnecessary exposure of patients to radiation.
Some patients showed increased levels of Tg but conventional imaging tests (the [ 131 I] scan, neck US, and/or chest radiography) do not reveal a pathological lesion. Therefore, other methods were required to locate the disease. In patients with elevated Tg levels, empirical high-dose RI treatment may be indicated, followed by a post-treatment [ ]-FDG-PET/CT has a diagnostic utility independent of that of Tg level, or even if the scan data are associated with Tg concentration. Some authors have reported that TSH elevation seems to improve scan sensitivity. In such patients, the incremental value afforded by hormonal stimulation of TSH is great because lesions that might be missed owing to their small size or low metabolic activity become apparent (25, 26) . This is why TSH significantly increases [ 18 F]-FDG uptake in DTC patients experiencing recurrence; TSH stimulates GLUT-1 expression and thus indirectly increases glucose transport. The stimulation afforded by TSH is real. However, other reports found no increase in the accuracy (sensitivity) of scan data obtained after hormonal TSH stimulation (27, 28) . Accordingly, no consensus on the effect of TSH stimulation on FDG-PET accuracy has been attained and it is important to render scanning cost-effective (18) . In the present study, the results Fig. 2) .
Iodine-124 is a positron-emitting isotope and is therefore suitable for use in PET imaging. The half-life is 4.2 days and the decay scheme is complex, resulting in additional radiation coincidence detection that is either non-destructive in terms of image quality or partially destructive (29, 30) . Recently, the isotope has been used for thyroid cancer imaging using high-resolution PET, and a combination of [
124 I]-PET and CT increased the clinical application of such a modality in thyroid cancer patients; detailed anatomical information and the location of iodine-positive tissue are provided (19-22, 29, 30) . The [
124 I] isotope has also been used in dosimetric studies and for thyroid volume measurement (13, (20) (21) (22) (23) . Most reports found that [
124 I]-PET scanning was useful in terms of DTC staging before RI treatment, and did not materially affect the therapeutic radiation dose (18, (20) (21) (22) (23) Fig. 3 ). The technique yields useful information when the iodine-avidity of a distant metastatic region has not previously been reliably assessed (for example, in patient 11; Fig. 4) .
Our study had several limitations. First, we enrolled only a small number of participants, and a large prospective trial is required to definitively evaluate our data. Second, our follow-up period was relatively short; years or decades of follow-up must pass before statistically reliable data can be obtained; this reflects the epidemiological and prognostic features of DTC. Finally, it is important to establish uniform standards for the conduct of scans, and to develop guidelines permitting comprehensive interpretation of test results, before the possible superiority of our [
18 F]-FDG-PET-plus-[ 124 I]-PET combination can be precisely compared with traditional follow-up protocols. The technique should be offered to only well-informed patients who thoroughly understand the advantages, limitations, and downside of determining cancer location. Our further studies will address these issues. Also, the histopathological and cytopathological characteristics associated with the ability of a tumor to avidly take up iodine, glucose, or both, require investigation.
Our findings showed that both [ 124 I]-PET/CT and [
18 F]-FDG-PET/CT are useful diagnostic tools when recurrence occurs in DTC patients who have elevated Tg levels but no definitive abnormalities by conventional imaging. Moreover, a combination of the two modalities provides an even greater diagnostic capacity, by which therapeutic decisions on additional surgery or RI treatment can be informed. However, it should be also noticed that considerable number of patients could not be detected by these imaging techniques, and therefore, continuing and further studies are still required.
